Neuropsychopharmacology Flashcards

1
Q

what Is the function of dopamine

A

Dopamine modulates attention and salience

“Salience” refers to the motivational properties of a stimulus, which can cause it to attract attention and drive behavior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how is dopamine linked to delusions

A

Dopamine modulates attention and salience

“Salience” refers to the motivational properties of a stimulus, which can cause it to attract attention and drive behavior

Aberrant salience hypothesis:

Abnormal dopamine nuerotransmission

Tendency for irrelevant stimuli to be attributed motivational salience and thus to attract attention and influence behaviour inappropriately - brain thinks everything is important and then the brain gives a meaning for these things - leads to delusions

These are attended to, explored and given meaning – leads to formation of delusions - what meaning is given is dependent to personal circumstances - eg in NI they’ll relate it to paramilitary or psi or mi5 or something but in America it’ll be via or fbi or something like that

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What causes schizophrenia

A

Genetic risk
first degree relative increases risk to 8-10%
Shared risk with bipolar disorder

Cannabis use in teenage years increases risk x2

Childhood trauma

Social isolation e.g. increased risk in immigrant groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

describe Schizophrenia symptoms

A

Positive symptoms:

  • Delusions, hallucinations, impaired insight
  • Distressing
  • Respond well to antipsychotics

Negative symptoms:

  • Emotional blunting, social withdrawal, apathy
  • Can be very disabling and require long term support
  • tend to be more disabling and difficult to treat

Cognitive impairment

  • Pattern of impairments
  • Drop in IQ
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe the dopamine hypothesis in Schizophrenia

A

There are significant abnormalities in dopamine transmission in the striatum

  • Elevated pre-synaptic dopamine synthesis and storage
  • Increased dopamine release from cells
  • Increased density of D2 receptors in striatum

Antipsychotic effectiveness associated with blockade of D2 receptors in striatum

Cannabis – causes increased striatal dopamine release

Other genetic and environmental risk factors associated with abnormalities in dopamine transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what’s the difference between 1st vs 2nd generation / Typical vs Atypical drugs in Schizophrenia treatment

A

Originally termed ‘atypical’ as not thought to produce Extra Pyramidal Side effects (EPSE) at treatment doses

2nd generation / atypical more likely to produce metabolic side effects

No difference in efficacy

2nd generation have broader receptor profile – not limited to dopamine receptor antagonism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

describe the pharmacology of antipsychotics

A

Antipsychotics are antagonists at dopamine D2 receptors – this mediates their clinical effect

They improve positive (psychotic) symptoms, but no impact on negative symptoms

Concordance enhanced by DEPOT preparations:
- Haloperidol, zuclopenthixol, risperidone, aripiprazole

Antipsychotics also act at a number of other receptors:

  • Serotonin
  • Histamine
  • Muscarinic
  • Alpha adrenergic

Both positive and adverse effects mediated by action at other receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the adverse effects of dopamine antagonism

A
  1. Nigrostriatal tract - Extra pyramidal side effects (EPSE) (Extrapyramidal side effects: Physical symptoms, including tremor, slurred speech, akathesia, dystonia, anxiety, distress, paranoia, and bradyphrenia, that are primarily associated with improper dosing of or unusual reactions to neuroleptic (antipsychotic) medications.)
  2. Tuberoinfundibular system – prolactin elevation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the four Extra pyramidal side effects (EPSE)

A
  1. Acute dystonia;
    - Involuntary muscle spasm
    - Occurs within hours of starting antipsychotics
    - Torticollis / oculogyric crisis / tongue spasm
    - Imbalance between nigrostriatal dopamine / acetylcholine – rapidly respond to IM anticholinergic e.g. procyclidine / benzhexol
    - More common in young males / antipsychotic naïve / high potency e.g. haloperidol
  2. Parkinsonism:
    - Characteristic signs:
    Tremor (“pill-rolling”)
    Rigidity (cogwheel)
    Bradykinesia
    - Develops days to weeks after antipsychotic treatment
    - Risk factors: elderly females, first generation antipsychotics
    - Nigrostriatal dopamine blockade leads to relative excess of acetylcholine
    - Treatment:
    Add anticholinergic e.g. procyclidine
    Reduce antipsychotic dose
    Switch to second generation antipsychotic
  3. Akathisia:
    - A subjectively unpleasant state of inner restlessness where there is a strong desire to move:
    Foot stamping when seated
    Crossing/uncrossing legs
    Rocking foot to foot
    Pacing up and down
    - Associated with increased risk of suicide and aggression
    - Pathology less clear
    - Occurs in 25% patients, less with 2nd generation (except risperidone and aripiprazole)
    - Treatment:
    Reduce dose
    Switch to 2nd generation antipsychotic
    Anticholinergics unhelpful
    Propranolol and 5HT2 antagonists e.g. mirtazapine may help but limited evidence
  4. Tardive Dyskinesia:
    - Abnormal movements
    Lip smacking and chewing
    Tongue movements (‘fly catching’)
    Choreiform hand movements
    Pelvic thrusting
    - 5% patients per year of antipsychotic exposure
    - More common in elderly women and people who have had early EPSE
    - Treatment:
    Increasing antipsychotic may improve symptoms initially
    Stop anticholinergic
    Reduce dose of antipsychotic
    Switch to Quetiapine or Clozapine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe Hyperprolactinaemia

A

Dopamine inhibits prolactin release therefore antipsychotics can increase prolactin levels

Olanzapine, aripiprazole, clozapine and quetiapine do not increase prolactin at usual treatment doses

May be asymptomatic

Problems include: sexual dysfunction, breast growth and galactorrhoea (excessive or inappropriate production of milk), reduction in bone mineral density and menstrual disturbances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe the metabolic side effects of antipsychotics

A

More common with 2nd generation antipsychotics

Include
Weight gain
Dyslipidaemia
Type 2 diabetes

Weight gain:

  • Mediated by serotonin 5HT2C, 5HT1A and H1 antagonism
  • Worst with clozapine and olanzapine
  • Likely genetic susceptibility

Dyslipidaemia:

  • Increased by lifestyle factors prevalent in individuals with schizophrenia - not eating well, not attending GP as much as they should, not exercising enough
  • Also exacerbated by antipsychotics esp Clozapine, Olanzapine and Quetiapine
  • Likely associated with weight gain, although precise receptor associations unclear

Type 2 Diabetes:

  • Lifestyle factors
  • Untreated people with schizophrenia at higher risk
  • Overall approx. 13% people with schizophrenia vs 3% general pop
  • Mediated by weight gain, but also likely to be direct antipsychotic effect
  • Clozapine, olanzapine > Quetiapine > other 2nd gen antipsychotics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

name the non-metabolic side effects of antipsychotics

A

Sedation (Histamine receptor antagonism)

Dry mouth, constipation (Muscarinic antagonism)

Postural hypotension (Adrenergic receptor antagonism)

Sexual dysfunction (serotonergic antagonism, plus the above)

QTc prolongation

Neuroleptic malignant syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

describe Neuroleptic malignant syndrome

A

Idiosyncratic response to antipsychotics

Caused by D2 receptor blockade

More likely with 1st generation antipsychotics

Symptom:

  • Fever, confusion, muscle rigidity
  • Autonomic disturbance
  • Rhabdomyolysis (Raised CK) – renal failure

Treatment:

  • Stop antipsychotic
  • Supportive
  • Restart 2nd generation cautiously
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when Is clozapine used and what are its side effects

A

Reserved for use in treatment resistant schizophrenia

2 trials of antipsychotic, minimum 6 weeks

Side effects:

  • Neutropenia→agranulocytosis (deficiency in granulocytes)
  • Myocarditis (inflammation of heart)
  • Hypersalivation (excessive production of saliva)
  • Constipation – potentially severe
  • Sedation and weight gain

more effective than any other antipsychotic
but use restricted because it has some severe side effects
most people tolerate it v well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

when Is aripipazole used and what are its side effects

A

NOT A DOPAMINE ANTAGONIST! – a partial agonist at dopamine D2 receptors

Functionally acts as antagonist in presence of increased dopamine transmission in mesolimbic area

Acts as agonist in mesocortical area

Side effects include akathisia and agitation but no other EPSE, weight gain, sedation or hyperprolactinaemia - not a lot of side effects - no metabolic side effects - not sedative

no evidence that it treats negative symptoms

IF it works - can be very effective because of its side effects profile - difficulty is it doesn’t work for everybody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the indications for antipsychotics

A

Schizophrenia

Other psychotic disorders:

  • Delusional disorder
  • Severe depression with psychotic symptoms
  • Mania with psychotic symptoms

Non-psychotic disorders:

  • Maintenance in bipolar affective disorder
  • Adjunctive treatment in depression
  • Evidence in OCD, PTSD, ASD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what needs to be monitored when you have prescribed antipsychotics

A
Weight
Prolactin
Blood glucose
ECG
U&E
Blood pressure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is the difference between psychosis and neurosis

A

PSYCHOSIS:
- Characterized by delusions (Fixed false belief out of keeping with a person’s religion and culture), hallucinations (A perception in the absence of a stimulus) and impaired insight (The individual is not aware of the problem – although apparent to others) eg schizophrenia
- E.g:
> Schizophrenia
> Schizoaffective disorder
> Delusional disorder
> Severe depressive disorder and mania may also exhibit psychotic symptoms

NEUROSIS:

  • “disorders of sense and emotion”
  • No delusions or hallucinations.
  • Insight intact
  • Eg mood and anxiety disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

describe mania/hypomania

A

A pathological mood state lasting >= 4 days characterized by:

  • Elated or irritiable mood
  • Overactivity
  • Increased energy
  • Grandiosity
  • Disinhibition
  • Increased libido
  • Note mania may be associated with grandiose delusions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what is the difference between nicotinic and muscarinic acetylcholine receptors

A

Nicotinic:

  • Ionotropic (fast)
  • Predominant in PNS

Muscarinic:

  • Metabotropic (slow)
  • Predominant in CNS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe in outline how antidepressants are used in the treatment of depression

A

Chronic stress alters neuronal circuits in brain

Antidepressants increase BDNF and stimulate neurogenesis – enhance synaptic plasticity

Moderates limbic system to reduce negative cognitive bias

Increased serotinergic neurotransmission modulates other neurotransmitter systems eg GABA, dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

describe the mode of action of SSRIs

A

Selective serotonin reuptake inhibitors

Prevents re-uptake and subsequent degradation of the monoamine neurotransmitter serotonin from the synaptic cleft

Overall effect: Prolonged presence of serotonin in the synaptic cleft leads to prolonged neuronal activity – in mood disorders such as depression there are low levels of this neurotransmitter in the brain. SSRIs therefore restore the concentration of serotonin to normal levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

describe some SSRI side effects

A
  • Well tolerated
  • Relatively safe in overdose
  • First line treatment (NICE)
  • GI – nausea, vomiting, dyspepsia
  • Headache
  • Agitation, anxiety
  • Sexual dysfunction
  • Hyponatraemia
  • Increased risk of bleeding
  • +/- Insomnia
  • NO weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what are some interactions of SSRIs

A

Dangerous in combination with other antidepressants and St John’s Wort

CYP enzyme inhibitors – increase levels of antipsychotics, benzodiazepines

Citalopram / Escitalopram – QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

describe the mode of action of SNRIs (Serotonin and Noradrenaline reuptake inhibitors)

A

Effect: Prevents re-uptake and subsequent degradation of the monoamine neurotransmitters
serotonin and noradrenaline from the synaptic cleft

Overall effect: Prolonged presence of serotonin and noradrenaline in the synaptic cleft leads to prolonged neuronal activity – in mood disorders such as depression there are low levels of these neurotransmitters in the brain. Serotonin/noradrenaline reuptake inhibitors therefore restore the concentration to normal levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

describe some side effects for SNRIs

A
GI – nausea, vomiting, dyspepsia
Headache
Agitation, anxiety, 
Sexual dysfunction
Hyponatraemia
Sweating
\+/- Insomnia
Elevation of blood pressure at higher doses
NO weight gain,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what are the interactions of SNRIs

A

Dangerous in combination with other antidepressants and St John’s Wort

Metabolized by CYP2D6/34A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

give some examples of SSRIs

A

Sertraline (Lustral): 50-200mg

Fluoxetine (Prozac): 20-60mg

Citalopram (Cipramil): 20-40mg

Escitalopram (Cipralex): 10-20mg

Paroxetine (Seroxat): 20-50mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

give 2 examples of SNRIs

A

Venlafaxine (Efexor, Vensir): 75 – 375mg

Duloxetine (Cymbalta): 60-120mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

name the NASSA (Noradrenergic and Specific Serotonergic antagonists) drug

A

Mirtazapine (Zispin): 15-45mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

describe the mode of action of NASSAs (Noradrenergic and Specific Serotonergic antagonists)

A

blocks the noradrenaline a2 autoreceptor

this blocks the negative feedback

and causes an increase in release of serotonin and adrenaline in the synaptic cleft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

describe the mode of action of NASSAs (Noradrenergic and Specific Serotonergic antagonists)

A

blocks the noradrenaline a2 autoreceptor

this blocks the negative feedback

and causes an increase in release of serotonin and adrenaline in the synaptic cleft

Post synapticly:

  • antagonist at 5-HT 1 and 5-HT3 receptors
  • enhances 5-HT1 neurotransmission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

describe the side effects of Mirtazapine

A
  • Drowsiness, sedation
  • Increased appetite and weight gain
  • Dizziness
  • Potential for blood dyscrasia
  • Sexual dysfunction uncommon
  • Few interactions
  • CAN be used in combination with SSRI/SNRI with caution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

list some Tricycic Antidepressants

A

Amitriptyline: 50-200mg/day

Clomipramine: 30-250mg/day

Lofepramine: 140-210mg/day

Dosulepin: 75-225mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

describe the mode of action of Tricycic Antidepressants

A

Target: Noradrenaline and serotonin reuptake transporters on the pre-synaptic neuronal membrane Action: Inhibitor

Effect: Prevent re-uptake and subsequent degradation of the monoamine neurotransmitters serotonin and noradrenaline from the synaptic cleft

Overall effect: Prolonged presence of serotonin and noradrenaline in the synaptic cleft leads to prolonged neuronal activity – in mood disorders such as depression there are low levels of these neurotransmitters in the brain. TCAs therefore restore the concentration to normal levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

what are some side effects of tricyclics

A

Not recommended first line

Less well tolerated than other antidepressants

Potentially fatal in overdose

Dangerous in combination with other antidepressants and St John’s Wort

Other indications – eg amitriptyline and pain

  • General:
    Nausea, vomiting, headache
  • Histamine receptor:
    Sedation, hangover
  • Alpha 1 receptor antagonism:
    Postural hypotension, tachycardia, arrhythmia
  • Anticholinergic:
    Dry mouth, blurred vision, constipation, urinary retention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

list some MAOIs (Monoamine oxidase inhibitors)

A

Reversible: Moclobemide

Irreversible: Phenylzine, Tranylcypromine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

list some MAOIs (Monoamine oxidase inhibitors)

A

Reversible: Moclobemide

Irreversible: Phenylzine, Tranylcypromine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

describe the mode of action of MAOIs (Monoamine oxidase inhibitors)

A

An enzyme called monoamine oxidase is involved in removing the neurotransmitters noradrenaline, serotonin and dopamine from the brain. MAOIs prevent this from happening, which makes more of these brain chemicals available to effect changes in both cells and circuits that have been impacted by depression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

list some side effects of MAOIs

A

Rarely used in clinical practice

Possible role in treatment resistant depression

Dangerous in combination with other antidepressants and St John’s Wort

CHEESE REACTION:
Tyramine is contained in certain foods: aged cheeses, chicken liver, soy products, pickled fish and red wine

Tyramine normally inactivated by MAO in GIT

Patients on MAOIs cannot metabolize tyramine

Tyramine causes release of catecholamines resulting in tachycardia, hypertension, arrhythmias, seizures and stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

list some side effects of MAOIs

A

Rarely used in clinical practice

Possible role in treatment resistant depression

Dangerous in combination with other antidepressants and St John’s Wort

CHEESE REACTION:
Tyramine is contained in certain foods: aged cheeses, chicken liver, soy products, pickled fish and red wine

Tyramine normally inactivated by MAO in GIT

Patients on MAOIs cannot metabolize tyramine

Tyramine causes release of catecholamines resulting in tachycardia, hypertension, arrhythmias, seizures and stroke

also:

  • Postural hypotension
  • Drowsiness
  • Insomnia
  • Headaches
  • Anticholinergic effects
  • Weight gain
  • Parathesia
  • Hepatotoxicity
  • Leucopenia
  • Hypertensive crisis
42
Q

describe the mode of action of vortioxetine

A
Serotonin reuptake(SERT) inhibitor:
- Serotonin reuptake inhibition

5HT-1A receptor Agonist:

  • Post-synaptic: enhances sertoninergic neurotransmission
  • Pre-synaptic: Leads to desensitisation of 5HT1A autoreceptors and enhanced 5HT release

Other serotinergic activity:

  • Enhances serotinergic neurotransmission
  • Thought to mediate other neurotransmitter systems: Dopamine, GABA, glutamate, acetylcholine
43
Q

list some adverse effects of vortioxetine

A

Metabolised by p450 system

Common adverse effects: nausea, vomiting, diarrhoea, dry mouth, headaches, abnormal dreams

Less sexual dysfunction

“pro cognitive” effects

44
Q

describe some discontinuation symptoms of antidepressants

A

Occur on abrupt cessation of antidepressants

Onset within 5 days:

  • Irritability
  • Nausea
  • Sweating
  • Paraesthesia, ‘electric shock’ sensations
  • Dreaming
  • Usually mild and self limiting but can be severe
  • Up to 1/3 of patients
  • Can occur with ANY antidepressant
  • Worst with short half life – paroxetine, venlafaxine
  • NOT relapse
  • NOT addiction
  • Can be avoided by gradual withdrawal of antidepressant
45
Q

describe the NICE guidelines for antidepressant use

A

Do not routinely treat mild depression with antidepressants

Psychosocial interventions for mild-moderate depression

Antidepressant treatment combined with psychosocial interventions for mod-severe depression

Monitor for suicidality if <30 years old

  1. SSRI 1st line
  2. If ineffective/intolerable then switch
    - Alternative SSRI
    - Another class of antidepressant
  3. Augment
    - Lithium
    - Antipsychotic
    - Mirtazapine
  4. ECT
46
Q

when is electroconvulsive therapy used

A

Severe depression which is life threatening and rapid response required
OR
Not responded to treatment

More effective than antidepressants, faster response rate

47
Q

describe the neurobiology of manic episodes and depressive episodes in bipolar disorder

A

Manic episodes:

  • Increased DOPAMINE neurotransmission
  • Increased GLUTAMATE transmission
  • Reduced GABA neurotransmission
  • Role for SEROTONIN and NORADRENALINE?

Depressive episodes:

  • Possible role for DOPAMINE dysregulation in bipolar depression
  • Antidepressants can cause a switch to mania
48
Q

what are the general principles for treatment in bipolar disorder

A
  1. Treatment of bipolar depression
  2. Treatment of manic episodes
  3. Prevention of relapse
49
Q

how would you treat mania in bipolar disorder

A

STOP ANTIDEPRESSANTS!

Antipsychotic is main treatment:

  • Haloperidol, olanzapine, risperidone, quetiapine
  • Aripiprazole
  • Lithium, valproate - slower than antipsychotics so not given as first line treatment
  • If already on long term treatment – optimize dose +/- add on
50
Q

how would you treat depression in bipolar disorder

A

response to antidepressants is different to normal depression - they barely respond to antidepressants

Quetiapine, Olanzapine (+/- fluoxetine)

Lamotrigine

Lithium – less effective

ECT - for severe bipolar depression

Consider psychological treatments eg CBT

51
Q

describe how you would try to prevent relapse in bipolar disorder

A

Protect against manic relapse:
- Lithium, Olanzapine, Quetiapine, Risperidone, Valproate

Protect against depressive relapse:
- Lamotrigine, lithium and Quetiapine

Best evidence for long term efficacy – LITHIUM:
- If lithium not tolerated/ineffective then valproate > antipsychotics

52
Q

describe the mode of action of lithium use as a mood stabiliser

A

reduces presynaptic dopamine - inactivates post synaptic G-proteins - modulates neurotransmission with action on 2nd messenger systems

down regulates NMDA receptor - modulates neurotransmission with action on 2nd messenger systems

facilitates release of GABA - up regulates GABA-B receptor

53
Q

describe the pharmacokinetics of lithium

A

Absorbtion complete 6-8 hours, peak level 30mins to 2 hours

Distributed in total body water, slow entry to intracellular compartment

No protein binding, Not metabolized

Excreted entirely in urine in similar way to sodium.

Half life 20 hours

54
Q

describe the side effects of lithium

A

Tends to be very well tolerated - good long term treatment

RENAL:

  • Polyuria and polydipsia
  • Potentially nephrotoxic
  • Check U&E and serum creatinine and eGFR prior to commencing

THYROID:

  • Hypothyroidism in up to 20%
  • more common in females, FHx
  • If hypothyroidism develops - continue lithium and treat with thyroxine.
  • TFT’s usually return to normal after stopping lithium.

OTHER SIDE EFFECTS:

  • Leukocytosis (most patients)
  • Polyuria/polydipsia (30-50%), dry mouth (20-50%)
  • Fine hand tremor (45% initially, 10% after 1 year of treatment)
  • Minor cognitive effects: verbal learning, memory and creativity
  • Muscle weakness (30% initially, 1% after 1 year of treatment)
  • Electrocardiographic (ECG) changes (20-30%)
  • Nausea, vomiting, diarrhoea (10-30% initially, 1-10% after 1-2 years of treatment)
  • Weight gain
55
Q

list some contraindications for lithium

A
  • Pregnancy - relative - can have a mild teratogenic effect
  • Breast-feeding
  • Renal impairment
  • Thyroidopathies
  • Sick sinus syndrome
56
Q

describe lithium toxicity symptoms

A

when a patient has taken too much

MILD:

  • Weakness
  • Worsening tremor
  • Mild ataxia
  • Diarrhoea

WORSENING TOXICITY:

  • Vomiting
  • Coarse tremor
  • Slurred speech
  • Confusion

SEVERE:
- Seizures →Coma→Death

57
Q

describe the causes of lithium toxicity

A

Overdose – intentional or accidental

Older patients – more vulnerable to toxicity, and at lower levels

Factors affecting salt/water balance:
- Dehydration, sweating, vomiting

Medications which alter lithium excretion through their effect on the kidneys:

  • Thiazide diuretics
  • ACE inhibitors
  • NSAIDs
  • COX-2 inhibitors
58
Q

describe the treatment for mild moderate and severe lithium toxicity

A

Mild:
- Supportive, stop lithium

Moderate:
- Fluid infusion – saline diuresis

Severe (eg Li >4.0 mmol/L or altered level of consciousness):
- May need haemodialysis

Mortality - <1% of all toxic exposures

59
Q

describe the mode of action of sodium valproate as a mood stabiliser

A

Mode of action not well understood – enhances GABA neurotransmission

Metabolized in liver by CYP – enzyme INHIBITOR

Increases concentrations of lamotrigine, amitriptyline

Forms: sodium valproate, semi-sodium valproate (Depakote)

60
Q

describe the use of sodium valproate as a mood stabiliser

A

Used in maintenance treatment, and to treat acute mania

Dose 500-2000mg daily (often as semisodium valproate – ‘Depakote’)

Rapid loading

Reduced need for monitoring and better tolerated than lithium

Check LFT/FBP baseline and 6 months

DO NOT USE IN WOMEN OF CHILDBEARING AGE

61
Q

describe some of the side effects of sodium valproate

A
Common:		
Nausea, vomiting
Drowsiness
Dizziness
Weakness
Weight gain
Uncommon:
Encephalopathy
Liver failure
Pancreatitis
Low platelets – increased bleeding risk
Teratogenic
62
Q

describe the mode of action of lamotrigine as a mood stabiliser

A

Mode of action – acts on pre-synaptic voltage gated sodium channels to reduce glutamate neurotransmission

Metabolism by glucuronic acid conjugation – fewer drug interactions

Level reduced by OCP

Level increased by Valproate

63
Q

describe when lamotrigine is used in bipolar disorder

A

Use in maintenance particularly to prevent bipolar depression

Limited use in acute mood state – limited by slow titration

Not first line

64
Q

describe some side effects of lamotrigine

A
  • Associated with severe skin reactions – Steven Johnson Syndrome, Toxic epidermal necrolysis
  • Risk 0.1%, occurs in 2-8 weeks. Risk reduced by slow titration
  • Other side effects: loss of balance and coordination, nausea, dizziness, drowsiness, insomnia, change in menstrual periods, blurred vision
65
Q

describe the symptoms of mild moderate and severe Alzheimer’s disease

A

MILD:

  • Memory loss
  • Language problems
  • Mood and personality problems
  • Diminished judgement

MODERATE:

  • Behavioural and personality changes
  • Unable to learn or recall new information
  • Wandering, agitation, aggression or confusion
  • Need assistance with daily living

SEVERE:

  • Unstable gait, motor disturbances
  • Bedridden, incontinence, may be mute
  • Unable to attend to ADLs
66
Q

describe the pathophysiology of Alzheimer’s disease

A

Physiologically, Amyloid Precursor Protein (APP) is cleaved by α-secretase to produce soluble Amyloid Precursor Protein (sAPP)

IN Alzheimers, Amyloid Precursor Protein is abnormally cleaved by β-secretase and ɤ-secretase

This forms Beta-amyloid peptide (Aβ)

Beta-amyloid peptide (Aβ) aggregates to form oligomers (amyloid plaques)

Beta-amyloid plaques are toxic:

  • Oxidative stress
  • Pro-inflammatory
  • Altered calcium homeostasis

Tau proteins abnormally phosphorylated to cause neurofibrillary tangle formation leading to cell death

  • this leads to depletion of cholinergic neurones
  • therefore excessive glutamate release (and impaired re-uptake) leading to excitotoxicity of post synaptic cells
  • reduction also in serotinergic and noradrenergic neurones
67
Q

what drug treatments are used in Alzheimer’s disease

A

2 types:

Acetylcholinesterase inhibitors:

  • impair the breakdown of acetylcholine in the synaptic cleft by the enzyme acetylcholinesterase and increase availability of acetylcholine
  • Donepezil
  • Rivastigmine
  • Galantamine

NMDA (glutamate receptor) antagonist:

  • treats the excessive glutamate release and addresses the excitotoxicity caused by this
  • Memantine
68
Q

what are some side effects of acetylcholinesterase inhibitors

A

related to increased parasympathetic activity

  • Nausea, vomiting, diarrhoea
  • Bradycardia, syncope, heart block
  • Muscle cramps
  • Caution: sick sinus/conduction abnormalities, asthma, COPD
69
Q

describe Parkinson’s disease

A
  • A neurodegenerative disease resulting from death of dopaminergic cells in the substantia nigra
  • The nigrostriatal dopamine pathway projects from the substantia nigra in basal ganglia
  • Normally modulates voluntary movement - initiation of movement and inhibition of contradictory movements
  • Degeneration of this pathway results in symptoms of parkinsonism
  • Parkinsonism is characterised by bradykinesia, rigidity and tremor.
  • Idiopathic Parkinson’s disease commonest

Other causes:

  • Drug induced parkinsonism
  • Post encephalitic parkinsonism
  • Toxins e.g. manganese, carbon monoxide
70
Q

describe the symptoms of Parkinson’s disease

A

Motor:

  • Resting pill rolling tremor
  • Bradykinesia
  • Rigidity
  • Festinant/shuffling gait

Non Motor:

  • Fatigue, depression
  • Dysarthria, sialorrhoea
  • Micrographia
  • Cognitive impairment
71
Q

describe the role of Dopamine and acetylcholine in Parkinsons

A

Acetylcholine and dopamine are normally in ‘balance’

Acetylcholine release from the striatum is strongly inhibited by dopamine

Acetylcholine excess or dopamine depletion results in parkinsonism

72
Q

name some dopamine enhancing drugs and anticholinergic drugs used in treatment of Parkinson’s

A

Dopamine enhancing drugs:

  • Levodopa
  • Dopamine agonists
  • Apomorphine
  • COMT inhibitors
  • MAO-B inhibitors
  • Amantadine

Anticholinergic drugs:

  • Procyclidine
  • Orphenadrine
  • Benzhexol
73
Q

describe how levodopa is used in the treatment of Parkinson’s

A

Levodopa converted to dopamine by dopa decarboxylase

Dopamine does not cross the blood brain barrier (BBB) but levodopa does cross BBB.

Levodopa is therefore administered with a dopa decarboxylase inhibitor (eg carbidopa, benserazide) to reduce the peripheral metabolism of levodopa to dopamine – reduced side effects

MADOPAR = levodopa + benserazide

74
Q

describe the pharmacokinetics of levodopa (treatment for Parkinson’s)

A

Half life 1-3 hours, peak levels 1 hour - quickly metabolised

metabolized in liver, excreted in bile

Reduced absorption in protein rich meals – Ldopa competes with amino acids

Interaction with pyridoxine (vit B6) – Increases peripheral activity of dopa decarboxylase therefore reduces availability in brain

75
Q

name some adverse effects of levodopa (Parkinson’s treatment)

A

Psychiatric:
- Confusion, anxiety, psychotic symptoms

Peripheral:

  • Nausea, vomiting
  • Hypotension, arrythmias
  • Sweating, discolouration of skin/urine

Long term effects:

  • Wearing off
  • On/off phenomena
  • Freezing
  • Involuntary movement (dyskinesias)
76
Q

describe how dopamine agonists work in the treatment of Parkinson’s

A

Act directly on post synaptic dopamine receptors

Longer duration of action than levodopa

Two types:

  • Ergot derivatives e.g. Pergolide, Cabergoline - older
  • Non-ergot derivatives e.g. Ropinirole, pramipexole, rotigotine - newer

Non ergot derivatives are better tolerated and do not show the fluctations in efficacy shown with levodopa

77
Q

list some adverse effects of dopamine agonists

A

Peripheral adverse effects:

  • Nausea/constipation
  • Postural hypotension
  • Cardiac arrhythmia
  • Peripheral oedema
  • Retroperitoneal, pulmonary pericardial fibrosis***
  • **associated with ergot derivatives and requires monitoring

Central adverse effects:

  • Drowsiness (sudden onset of sleep)
  • Hallucinations
  • Psychotic reactions
  • Impulse control disorders
78
Q

give an example of a dopamine agonist used in treatment of Parkinson’s

A

apomorphine

Potent dopamine agonist
Used in advance disease
Used to treat ‘off’ period with levodopa
Administered subcutaneously

79
Q

describe how COMT inhibitors work in the treatment of Parkinson’s

give an example of one

A

Prevent the peripheral breakdown of levodopa by inhibiting catechol –O-methyltransferase

Reduces variations in plasma levodopa levels

‘continuous dopaminergic stimulation’

e.g. Entacapone, tolcapone

Adverse effects similar to levodopa and tolcapone is hepatotoxic

80
Q

describe how MAO-B inhibitors work in the treatment of Parkinson’s

A

MAO-B breaks down dopamine

Protects dopamine from extra-neuronal degradation, therefore increasing the extent and duration of the response to levodopa

Safety concerns –possible increased mortality on seleginine

Do not cause cheese reaction of non selective monoamine oxidase inhibitors (MAOI – antidepressant)

81
Q

describe the side effects of MAO-B inhibitors

A

Related to increased dopaminergic effects (cf L-Dopa)

Selegenine metabolized to amphetamine – anxiety, insomnia

82
Q

describe how Anticholinergic drugs could be used to treat Parkinson’s

name 2

give some side effects

A

e.g. Orphenadrine, procyclidine

Suppression of acetylcholine by acetylcholine antagonists (anticholinergics) helps to compensate for the lack of dopamine in Parkinson’s disease

Rarely used in Parkinson’s disease but can be used to treat the parkinsonian side effects of anti-psychotic drugs

SE: cognitive impairment, delirium, blurred vision, dry mouth, urinary retention

83
Q

briefly describe the neurobiology of anxiety

A

Hyperactivation of “fear network” involving amygdala and hippocampus

Hypoactivation of pre-frontal cortex - part of brain that modulates response to certain stimulus

84
Q

briefly describe generalised anxiety disorder

A
  • Continuous “free floating” anxiety
  • May be with or without panic
  • Common – up to 5% population, F>M
  • Genetic component - neuroticism (tendency to worry)
85
Q

describe treatment for generalised anxiety disorder

A
  • First line pharmacological treatment – SSRI
  • May worsen anxiety initially
  • 2nd line alternative SSRI or SNRI
  • Consider pregabalin
  • Benzodiazepines – Not recommended as long term treatment
  • Also evidence for Quetiapine and Buspirone
86
Q

briefly describe panic disorder

A
  • Episodes of severe acute anxiety (panic) not related to specific stimulus
  • Panic symptoms – highly distressing, often attributed to cardiac arrest
  • 2/3 will develop AGORAPHOBIA – fear of situations from which escape difficult or help not available
  • Less common than GAD (generalised anxiety disorder)
  • May be caused by traumatic events, hereditary component
87
Q

describe treatment for panic disorder

A
  • SSRi first line – may exacerbate symptoms initially
  • SSRI/SNRI 2nd line

Also consider:

  • Tricyclic antidepressants eg imipramine, clomipramine
  • Gabapentin (very rarely used) and sodium valproate
  • Benzodiazepines – useful in short term but assoc with worse outcome in longer term
88
Q

briefly describe Obsessive compulsive disorder

A

Characterized by:

  • obsessional thoughts – generate high levels of anxiety
  • Compulsive behaviour performed to reduce anxiety levels - eg they do the behaviour in response to the thought - by doing the behaviour it rationalises the irrational thought
  • Distinguish from obsessional personality - two different things
89
Q

describe treatment for OCD

A

1st line SSRI

  • titrate to maximum tolerated dose
  • May need 8-12 weeks

2nd line another SSRI or Clomipramine

Treatment resistance common

  • Augment with antipsychotic
  • Possible role for anti-glutamatergic drugs – memantine, lamotrigine
90
Q

briefly describe Post traumatic stress disorder (PTSD)

A
  • follows highly traumatic event
  • Persistent anxiety, intrusive memories, hypervigilance following highly traumatic event
  • High prevalence in NI vs rest of the world. (troubles) May be chronic and difficult to treat
  • Increased by nature of trauma, underlying neuroticism and previous MH problems
  • Often comorbid depression and substance misuse
91
Q

describe treatment for PTSD

A

1st line – sertraline, paroxetine (?any SSRI) and venlafaxine

2nd line – as above

Treatment resistance common

  • Add antipsychotic – risperidone and olanzapine
  • Prazocin
92
Q

describe treatment for simple phobias

A

Best evidence is for exposure therapy

Some evidence to suggest SSRIs helpful

No evidence for other pharmacological interventons

93
Q

how do benzodiazepines work when treating short term anxiety

A

Target: Benzodiazepine (BDZ) receptor on GABA-BDZ receptor complex

Action: Agonist

Effect: Increase affinity of the inhibitory neurotransmitter GABA for the GABAA receptor – this causes post-synaptic chloride ion channels to open

Overall effect: Increased flow of negative chloride ions into the neurone leading to hyperpolarisation of the membrane – this prevents further excitation

94
Q

list some side effects of benzodiazepines

A

Common:

  • Amnesia, ataxia (especially elderly); confusion; dependence, drowsiness and dizziness the next day (hang-over effect)
  • Psychomotor impairment

Important:

  • Ataxia leading to increased risk of falls in the elderly
  • Physical and psychological dependence
  • Respiratory depression
  • Tolerance

Also:
Interaction with alcohol at GABA receptor

95
Q

describe how diazepam works in treating short term severe anxiety

A

Target: Benzodiazepine (BDZ) receptor on GABA-BDZ receptor complex

Action: Agonist

Effect: Increase affinity of the inhibitory neurotransmitter GABA for the GABAA receptor – this causes post-synaptic chloride ion channels to open

Overall effect: Increased flow of negative chloride ions into the neurone leading to hyperpolarisation of the membrane – this prevents further excitation

96
Q

when is diazepam used in psychiatry

A

Short term use to manage anxiety / agitation

  • Crises
  • Specific situations
  • Psychosis / mania when sedation and anxiolytic effect required

May be used to terminate seizures – PR/IV

Long term use best avoided – limited efficacy and concerns re tolerance

Indicated for alcohol withdrawal syndrome (or chlordiazepoxide – Librium)

Note frequently misused “yellows, roches”

97
Q

describe Z-drugs (Zolpidem, zopiclone)

A

Non-benzodiazepines (different chemical structure)

Bind to benzodiazepine site at GABA-A receptor

Short onset of action

Specific to α-1 subtype – Hypnotic

Anticonvulsant and muscle relaxant only at high doses

Side effects otherwise similar to benzodiaepines

98
Q

compare benzodiazepines vs barbiturates

A

Benzodiazepines:
- When bound, benzodiazepines increase affinity of receptor for GABA, increasing frequency of opening of chloride channel

Barbituates:

  • Bind to different site than benzodiazepines – synergistic effect possible
  • increase duration of opening of chloride channel, and may act in absence of GABA at high doses, increasing risk of toxicity
99
Q

when is flumazenil used and describe how it works

A

treatment of benzodiazepine overdose

  • Competitive antagonist in benzodiazepine binding site
  • Displaces Benzodiazepines – can treat OD
  • Rapid onset of action, short half life (needs repeated doses)
  • No effect on barbituates
  • Should not be used when benzos are used to treat epilepsy
  • Metabolised in liver
100
Q

when is pregabalin used and describe how it works

A

Anticonvulsant (mostly used for this), anxiolytic and neuropathic pain

Structural derivative of GABA – however does NOT bind to GABA receptors

Inhibitory action at presynaptic voltage gated calcium channels – modulates release of excitatory neurotransmitters inc glutamate and noradrenaline

Licence for GAD

Negligible metabolism – excreted largely unchanged in urine

Limited by potential for misuse (“buds”) - can give you a high

101
Q

when is bus-irons used and how does it work

A

Agonist at presynaptic 5HT-1A receptors, partial agonist at postsynaptic 5HT-1A receptors

No action at GABA receptors

Supresses serotinergic neurotransmission

Presynaptic dopamine antagonist D2/D3 receptors

No sedation / anticonvulsant activity

Efficacy = diazepam in GAD, Adjunct to SSRIs in depression

Mode of action unclear